Linked Life Data

18624684

Source:http://linkedlifedata.com/resource/pubmed/id/18624684

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2008-7-15
pubmed:abstractText
After the tragic events in the early 1960s, thalidomide has re-emerged as therapeutic for multiple myeloma (MM). It was first approved for the treatment of erythema nodosum leprosum, and is now under evaluation for hematologic and non-hematologic disorders. Its complex mechanism of action is not fully understood; however extensive preclinical studies in MM have revealed its antiangiogenic and immunomodulatory properties.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1742-5255
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
973-85
pubmed:dateRevised
2009-11-16
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
pubmed:affiliation
Dana-Farber Cancer Institute, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. Iris_Breitkreutz@dfci.harvard.edu
pubmed:publicationType
Journal Article, Review